StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a buy rating in a report released on Thursday.
Separately, Truist Financial dropped their price target on shares of Compugen from $5.00 to $4.00 and set a buy rating for the company in a research report on Tuesday, May 21st.
Read Our Latest Report on CGEN
Compugen Stock Performance
Compugen (NASDAQ:CGEN – Get Free Report) last announced its quarterly earnings results on Monday, May 20th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The company had revenue of $2.56 million during the quarter, compared to analyst estimates of $2.79 million. Sell-side analysts predict that Compugen will post 0.05 EPS for the current fiscal year.
Institutional Trading of Compugen
A hedge fund recently bought a new stake in Compugen stock. Heron Bay Capital Management acquired a new stake in Compugen Ltd. (NASDAQ:CGEN – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Compugen
- Where Do I Find 52-Week Highs and Lows?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- About the Markup Calculator
- MarketBeat Week in Review – 6/24 – 6/28
- 3 Warren Buffett Stocks to Buy Now
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.